| Patent(s) and the Corresponding Patented Drug(s) |
Top |
| World Intellectual Property Organization (WIPO) |
| Patent ID |
WO2016011390 |
| Title |
Irak4 Inhibiting Agents. |
| Abstract |
Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production. |
| Applicant(s) |
Biogen Ma Inc |
| Patent ID |
WO2015193846 |
| Title |
Substituted Indazole Compounds As Irak4 Inhibitors. |
| Abstract |
The present invention provides substituted indazole compound of formula (I) and pharmaceutically acceptable salts thereof, and their use to inhibit IRAK4 and/or for the treatment of diseases or disorders induced by IRAK4. |
| Applicant(s) |
Aurigene Discovery Technologies Limited |
| Patent ID |
WO2015150995 |
| Title |
Bicyclic-Fused Heteroaryl or Aryl Compounds and Their Use As Irak4 Inhibitors. |
| Abstract |
Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed. |
| Applicant(s) |
Pfizer Inc |
| Patent ID |
WO2015104662 |
| Title |
Indazole Compounds As Irak4 Inhibitors. |
| Abstract |
The present invention provides indazole compound of formula (I), which are therapeutically useful as kinase inhibitor, particularly IRAK4 inhibitors. wherein Z1, Z2, R1, R2, R3, 'm' and 'n' have the meanings given in the specification, and pharmaceutically acceptable salts or stereoisomers thereof that are useful in the treatment and prevention of diseases or disorder, in particular their use in diseases or disorder mediated by kinase enzyme, particularly IRAK4 enzyme. The present invention also provides pharmaceutical composition comprising at least one of the compounds of compound of formula (I) together with a pharmaceutically acceptable carrier, diluent or excipient therefor. |
| Applicant(s) |
Aurigene Discovery Technologies Limited |
| Patent ID |
WO2015103453 |
| Title |
Heteroaryl Substituted Nicotinamide Compounds. |
| Abstract |
Disclosed are compounds of Formula (I) or salts thereof, wherein: HET is a heteroaryl selected from pyrazolyl, indolyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[2,3-d]pyrimidinyl, pyrazolo[3,4-b]pyridinyl, pyrazolo[3,4-d]pyrimidinyl, 2,3-dihydro-1H-pyrrolo[2,3-b]pyridinyl, imidazo[4,5-b] pyridinyl, and purinyl, wherein said heteroaryl is substituted with Ra and Rb; and R1 and R2 are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases. |
| Applicant(s) |
Bristol-Myers Squibb Company |
| Patent ID |
WO2015091426 |
| Title |
Novel Carboxamides, Method for The Production Thereof, Pharmaceutical Preparations Comprising Them, and Use Thereof for Producing Medicaments. |
| Abstract |
The invention relates to a novel 6-substituted indazoles with carboxamide side chains, method for the production thereof, to the use thereof alone or in combinations for treating and/or the prophylaxis of diseases and to the use thereof for producing medicaments for treating and/or the prophylaxis of diseases, in particular for treating and/or the prophylaxis of endometriosis, preventing lymphomas, macular degeneration, COPD and psoriasis. |
| Applicant(s) |
Bayer Pharma Aktiengesellschaft |
| Representative Drug(s) |
D00WDA |
Drug Info
|
IC50 = 9 nM |
Click to Show More |
[1] |
|
2
|
D0DC8B
|
Drug Info
|
IC50 = 33 nM
|
[1] |
| Patent ID |
WO2014143672 |
| Title |
Macrocyclic Compounds As Irak4 Inhibitors for The Treatment of Inflammatory Diseases. |
| Abstract |
Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, wherein i.a. Ring A is phenylene or 5- to 6-membered heteroarylene; Ring B is phenylene, 5- to 6-membered heterocycloalkylene or 5- to 6-membered heteroarylen; R4 is absent, heteroarylene, arylene, C1-3 alkylene, or R4 and R3 taken together with the nitrogen to which they are bound form a 3- to 7-membered heterocycloalkyl ring; R5 is absent, C(0)NR51, NR52 or 0; R6 is C2-10 alkylene or alkenylene, wherein one or two of the carbon atoms in the alkylene chain is optionally replaced by an 0, S, SO, SO2 or NR61, and wherein two of the carbon atoms in the alkylene chain are optionally connected by a two or three carbon atom alkylene chain to form a 5- to 7-membered ring; R7 is absent, NR71 or O. The compounds are IRAK4 inhibitors useful for the treatment of inflammatory diseases. |
| Applicant(s) |
Biogen Ma Inc |
| Representative Drug(s) |
D0DK0R |
Drug Info
|
IC50 < 100 nM |
Click to Show More |
[1] |
|
2
|
D0GA8C
|
Drug Info
|
IC50 < 100 nM
|
[1] |
|
3
|
D0N5WE
|
Drug Info
|
IC50 < 100 nM
|
[1] |
|
4
|
D0Q7ZF
|
Drug Info
|
IC50 > 10000 nM
|
[1] |
| Patent ID |
WO2014121942 |
| Title |
Macrocyclic Pyridazinone Derivatives. |
| Abstract |
The present invention relates to compounds of formula (I) Wherein R1, R2, R3, R4, L and Z have the meaning given in claim 1, and their use in the prophylaxis and treatment of diseases. |
| Applicant(s) |
Merck Patent Gmbh |
| Patent ID |
WO2014074675 |
| Title |
Heteroaryl Substituted Pyridyl Compounds Useful As Kinase Modulators. |
| Abstract |
Compounds having the following formula (I) or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R2 is a monocyclic heteroaryl group, and R1, R3, R4, R5 and R6 are as defined herein, are useful as kinase modulators, including IRAK-4 inhibition. |
| Applicant(s) |
Bristol-Myers Squibb Company |
| Patent ID |
WO2014074657 |
| Title |
Bicyclic Heterocycle Substituted Pyridyl Compounds Useful As Kinase Modulators. |
| Abstract |
Compounds having the following formula (I) or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R2 is a bicyclic heterocycle, and R1, R3, R4, R5 and R6 are as defined herein, that are useful as kinase modulators, including IRAK-4 modulation. |
| Applicant(s) |
Bristol-Myers Squibb Company |
| Patent ID |
WO2014058691 |
| Title |
Inhibitors of Irak4 Activity. |
| Abstract |
The present invention relates to inhibitors of IRAK4 of Formula (I) and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases. |
| Applicant(s) |
Merck Sharp & Dohme Corp |
| Representative Drug(s) |
D0G3NC |
Drug Info
|
IC50 (IRAK4) = 1 nM |
Click to Show More |
[1] |
|
2
|
D04UIH
|
Drug Info
|
IC50 (IRAK4) = 32 nM
|
[1] |
| Patent ID |
WO2014058685 |
| Title |
Inhibitors of Irak4 Activity. |
| Abstract |
The present invention relates to compounds which modulate interleukin-l (IL-1 ) receptor-associated kinase 4 (IRAK4) and are useful in the prevention or treatment of inflammatory, cell proliferative and immune-related conditions and diseases. Specifically, provided herein are inhibitors of IRAK4 of Formula I and pharmaceutical compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases. |
| Applicant(s) |
Merck Sharp & Dohme Corp |
| Patent ID |
WO2014008992 |
| Title |
Pyrimidine Pyrazolyl Derivatives. |
| Abstract |
The present invention provides compounds of Formula (I) for the treatment of cancer, rheumatoid arthritis and other diseases (I). |
| Applicant(s) |
Ares Trading Sa |
| Patent ID |
WO2013106614 |
| Title |
Triazolyl-Substituted Pyridyl Compounds Useful As Kinase Inhibitors. |
| Abstract |
Compounds having the following formula:(I) wherein:A is an optionally substiuted triazole, or a stereoisomer or a pharmaceutically-acceptable salt thereof, are useful as kinase modulators, including IRAK-4 modulation. |
| Applicant(s) |
Bristol-Myers Squibb Company |
| Representative Drug(s) |
D0S1DI |
Drug Info
|
IC50 = 1.8 nM |
Click to Show More |
[1] |
|
2
|
D0L7OR
|
Drug Info
|
IC50 = 3.3 nM
|
[1] |
| Patent ID |
WO2013106612 |
| Title |
Heterocyclic-Substituted Pyridyl Compounds Useful As Kinase Inhibitors. |
| Abstract |
Compounds having the following formula: wherein A is, or; and X is N or C-R7, or an enantiomer, diastereomer or a pharmaceutically-acceptable salt thereof, are useful as kinase modulators, including IRAK-4 modulation. |
| Applicant(s) |
Bristol-Myers Squibb Company |
| Representative Drug(s) |
D0S1DI |
Drug Info
|
IC50 = 1.8 nM |
Click to Show More |
[1] |
|
2
|
D0L7OR
|
Drug Info
|
IC50 = 3.3 nM
|
[1] |
| Patent ID |
WO2013106535 |
| Title |
Irak Inhibitors and Uses Thereof. |
| Abstract |
The present invention provides thieno[2,3-d]pyrimidine derivative compounds, and pharmaceutical compositions thereof. The invention also includes methods inhibiting an IRAK protein kinase in a patient by administering the thieno[2,3-d]pyrimidine derivative compound. The invention also includes methods of treating an IRAK-mediated disorder, disease, or condition in a patient by administering the thieno[2,3-d]pyrimidine derivative compound. |
| Applicant(s) |
Nimbus Iris, Inc |
| Patent ID |
WO2013066729 |
| Title |
Aminopyrimidinones As Interleukin Receptor-Associated Kinase Inhibitors. |
| Abstract |
This invention relates to aminopyrimidinone compounds of Formula (I) that are inhibitors of Interleukin receptor-associated kinases, in particular IRAK-4, and are useful in the treatment or prevention of inflammatory diseases, including rheumatoid arthritis and inflammatory bowel disease. |
| Applicant(s) |
Merck Sharp & Dohme Corp |
| Patent ID |
WO2012084704 |
| Title |
Indazolyl Triazole Derivatives As Irak Inhibitors. |
| Abstract |
Compounds of Formula (I) are used for the treatment of inflammation and autoimmune disorders. |
| Applicant(s) |
Merck Serono S.A |
| Representative Drug(s) |
D0NT8U |
Drug Info
|
IC50 = 100 nM |
Click to Show More |
[1] |
|
2
|
D0O6GQ
|
Drug Info
|
IC50 < 100 nM
|
[1] |
| Patent ID |
WO2012007375 |
| Title |
Pyrazolo [1, 5A] Pyrimidine and Thieno [3, 2B] Pyrimidine Derivatives As Irak4 Modulators. |
| Abstract |
Compounds of the formula I or II: wherein X, m, Ar, R1 and R2 are as defined herein. The subject compounds are useful for treatment of IRAK-mediated conditions. |
| Applicant(s) |
F. Hoffmann-La Roche Ag |
| Representative Drug(s) |
D0E5AT |
Drug Info
|
IC50 = 31 nM |
Click to Show More |
[1] |
|
2
|
D0F2NW
|
Drug Info
|
IC50 = 107 nM
|
[1] |
| Patent ID |
WO2013042137 |
| Title |
Bicyclic Heterocycles As Irak4 Inhibitors. |
| Abstract |
The present invention provides bicyclic heterocycle kinase enzyme inhibitor compounds of formula (I), which may be therapeutically useful as kinase inhibitor, more particularly IRAK4 inhibitors. ( I ) in which A, R, R1,R2, m, n and p have the meanings given in the specification, and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention of diseases or disorder, in particular their use in diseases or disorder where there is an advantage in inhibiting kinase enzyme, more particularly IRAK4 enzyme.The present invention also provides pharmaceutical formulations comprising at least one of the kinase inhibitor compounds of formula (I) together with a pharmaceutically acceptable carrier, diluent or excipient therefor. |
| Applicant(s) |
Aurigene Discovery Technologies Limited |
| Representative Drug(s) |
D0W3TL |
Drug Info
|
IC50 < 50 nM |
Click to Show More |
[1] |
|
2
|
D0YF6E
|
Drug Info
|
N.A.
|
[1] |
| Patent ID |
WO2015068856 |
| Title |
Pyrazole for The Treatment Autoimmune Disorders. |
| Abstract |
The present invention provides a heterocyclic compound having an IRAK-4 inhibitory action, which is useful for the prophylaxis or treatment of inflammatory disease, autoimmune disease, osteoarticular degenerative disease, neoplastic disease and the like, and a medicament containing thereof. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof. |
| Applicant(s) |
Takeda Pharmaceutical Company Limited |
| Representative Drug(s) |
D0N4ZM |
Drug Info
|
N.A. |
Click to Show More |
[1] |
|
2
|
D0TV9G
|
Drug Info
|
N.A.
|
[1] |
|
3
|
D0VD3P
|
Drug Info
|
N.A.
|
[1] |
| Patent ID |
WO2012068546 |
| Title |
Heterocycle Amines and Uses Thereof. |
| Abstract |
Compounds and methods in the fields of chemistry and medicine are disclosed. Some of the disclosed embodiments include compounds, compositions and methods of using heterocycle amines. Some of the disclosed embodiments include heterocycle amines useful to treat inflammatory disorders. |
| Applicant(s) |
Ligand Pharmaceuticals Incorporated |
| Patent ID |
WO2015164374 |
| Title |
Irak Inhibitors and Uses Thereof. |
| Abstract |
The present invention provides quinazoline and quinoline compounds, compositions thereof, and methods of using the same. Also disclosed is the activity of such compounds as inhibitors of IRAK enzymes. |
| Applicant(s) |
Nimbus Iris, Inc |
| Patent ID |
WO2015048281 |
| Title |
Irak Inhibitors and Uses Thereof. |
| Abstract |
The present invention provides compounds, compositions thereof, and methods of using the same. |
| Applicant(s) |
Nimbus Iris, Inc |
| Patent ID |
WO2014121931 |
| Title |
Pyridazinone-Amides Derivatives. |
| Abstract |
The present invention relates to compounds of formula (I) wherein R1, Ra, Rb and Z have the meaning given in claim 1, and their use in the prophylaxis and treatment of diseases. |
| Applicant(s) |
Merck Patent Gmbh |
| Patent ID |
WO2012129258 |
| Title |
Amidopyrazole Inhibitors of Interleukin Receptor-Associated Kinases. |
| Abstract |
This invention relates to amidopyrazole compounds that are inhibitors of Interleukin receptor-associated kinases, in particular IRAK-4, and are useful in the treatment of cellular proliferative diseases, for example, cancer, hyperplasia, restenosis, cardiac hypertrophy, immune disorders and inflammation. |
| Applicant(s) |
Merck Sharp & Dohme Corp |
| Representative Drug(s) |
D0YJ1O |
Drug Info
|
IC50 (IRAK4) = 5 nM |
[1] |
| Patent ID |
WO2011043371 |
| Title |
Oxazole Compound. |
| Abstract |
Disclosed is a novel and excellent prophylactic and/or therapeutic method for diseases associated with interleukin-1 receptor-associated kinase-4 (IRAK-4), which is based on an interleukin-1 receptor-. |
| Applicant(s) |
Astellas Pharma Inc |
| Representative Drug(s) |
D0A2BX |
Drug Info
|
IC50 (IRAK4) = 0.24 nM |
[1] |
| Patent ID |
WO2014011911 |
| Title |
Irak Inhibitors and Uses Thereof. |
| Abstract |
The present invention provides furano- and pyrrolo- pyrimidine and pyridine compounds, compositions thereof, and methods of using the same. |
| Applicant(s) |
Nimbus Iris, Inc |
| Patent ID |
WO2014011906 |
| Title |
Irak Inhibitors and Uses Thereof. |
| Abstract |
The present invention provides thienopyridine compounds, compositions thereof, and methods of using the same. |
| Applicant(s) |
Nimbus Iris, Inc |
| Patent ID |
WO2014011902 |
| Title |
Irak Inhibitors and Uses Thereof. |
| Abstract |
The present invention provides arylo-fused thienopyrimidine compounds, compositions thereof, and methods of using the same. |
| Applicant(s) |
Nimbus Iris, Inc |
| Patent ID |
WO2012097013 |
| Title |
Irak Inhibitors and Uses Thereof. |
| Abstract |
The present invention relates to compounds and methods useful for inhibiting one or more interleukin-l receptor-associated kinases ("IRAK"). In some embodiments, a provided compound inhibits IRAK-1 and IRAK-4. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders. |
| Applicant(s) |
Nimbus Iris, Inc |
